A synthetic peptide whose sequence was derived from the circumsporozoite protein of Plasmodium knowlesi coupled to bovine gamma globulin has been shown to be immunogenic when administered with Freund complete adjuvant. The present experiments were designed to test the immunogenicity of the peptide when attached to a tetanus toxoid carrier and administered with alum or murabutide, both acceptable clinical adjuvants. In both cases, the use of an adjuvant increased the levels of circulating anti-peptide antibodies over those observed when no adjuvant was used. However, when the antisera were tested for reactivity with the native protein, animals of the group receiving the conjugate associated with murabutide always had titers greatly exceeding those observed in animals that received the conjugate with alum. Moreover, the sera of the murabutide-treated group were shown to be more active in eliciting shedding of the circumsporozoite protein than were sera of animals of the Freund complete adjuvant-treated group. The use of tetanus toxoid in secondary immunizations could be eliminated when the mice primed with peptide-tetanus toxoid and murabutide were boosted with a polymer of the peptide. The results indicate that the synthetic malarial peptide-tetanus toxoid conjugate is capable of stimulating high levels of biologically active antibodies only when administered with murabutide.
The sporozoite stage of Plasmodium knowlesi is highly immunogenic, and repeated injections of X-irradiated sporozoites have been shown to protect against malarial infection in mice, monkeys, and humans (4) . The identification and synthesis of a peptide representing a 24-amino-acid tandemly repeating epitope from the circumsporozoite protein of P. knowlesi has recently been reported (5) . Antibodies against this synthetic peptide, produced in rabbits, also cross-link the circumsporozoite protein on the membrane of the sporozoite and neutralize sporozoite infectivity (7a) . Other synthetic peptides representing epitopes from bacterial (1, 9, 10) and viral (2; L. Chedid, C. Carelli, and F. Audibert, Proc. Symp. Advances in Carriers and Adjuvants for Veterinary Biologics, Ames, Iowa, 7 and 8 May, 1984) pathogens have been shown to produce antibodies that recognize the natural structure when administered in saline with muramyl dipeptide or analogs. In the case of diphtheria toxin and of streptococci these antibodies were shown to be protective (1, 9 
MATERIALS AND METHODS
A synthetic 24-amino-acid peptide representing the immunodominant epitope of the sequence of the circumsporozoite protein of P. knowlesi was synthesized as previously described (5) . A second peptide with two additional amino acids, tyrosine at the N terminus and cysteine at the C terminus, was also synthesized to facilitate labeling and coupling of the peptide to carrier. The peptide was conjugated to a TT carrier (pep-TT) by using glutaraldehyde (1) or N-ethyl-N'-(3-dimethylamino)propyl-carbodiimide (6 
a BALB/c mice (six per group) received subcutaneously the conjugate in saline either alone or with adjuvant. At 4 weeks they were boosted with the same amount of conjugate without adjuvant. Anti-peptide titers were measured by ELISA 2 and 3 weeks after the boost, and anti-sporozoite titers were measured by RIA.
antipeptide antibodies was assessed by RIA with a sporozoite extract fixed to plastic plates (15), the circumsporozoite reaction (14) , and an indirect fluorescence antibody test (11) . RESULTS Anti-peptide response elicited by various dosages of pep-TT. The immunogenicity of the peptide alone or pep-TT and given with or without adjuvant was tested in experiments to determine the minimum dose of pep-TT needed under different adjuvant conditions (Table 1) . At all doses both alum and rthurabutide increased levels of circulating anti-peptide antibodies over saline controls; the highest titers were observed with the highest dose of pep-TT associated with murabutide. Third-week sera of mice receiving 100 p.g of pep-TT were tested for binding to the sporozoite. Sera from mice immunized with pep-TT in saline contained only a very low level of anti-peptide antibodies that recognized the sporozoite (titer, 300). Although the alum-treated group had high titers of anti-peptide antibodies by the ELISA procedure (110,000), minimal binding to the sporozoite could be detected (titer, 2,500). In contrast, sera from the murabutide group, which had comparable anti-peptide antibody titers by ELISA (150,000), had markedly higher anti-sporozoite antibody titers (25,000).
Boosting effect of pep-TT, free peptide, and polymerized peptide. Preliminary experiments showed that two administrations of the free peptide alone or peptide with murabutide could not elicit an anti-peptide response. In the following experiment mice (six per group) were primed with pep-TT associated with murabutide and received a boost of either the conjugate, the free peptide, or the polymerized peptide without adjuvant. By far the highest anti-peptide antibody titers both 1 week (day 35) and 2 weeks (day 42) after the boost were observed in the group treated twice with the conjugate, although on day 35 the polymerized peptide elicited a better secondary response than did the free peptide ( (Table 3) . Moreover, as previously observed, the anti-sporozoite antibodies as measured by RIA were increased. The use of either murabutide in saline or Freund complete adjuvant resulted in higher anti-sporozoite titers than did alum treatment. However, when these sera were tested for reactivity with the native protein in the circumsporozoite assay, titers for the murabutide-treated group were higher. It must be stated, however, that in mice titers obtained after immunization with P. knowlesi peptides are lower than those obtained after immunization by the natural pathogen of the mouse, Plasmodium berghei sporozoite (14) . Although the levels of anti-peptide antibodies in the alum treated group were high, sera from these mice did not elicit the circumsporozoite reaction. It is likely, based on earlier results obtained by immunization with attenuated intact sporozoites in rhesus monkeys, that anti-circumsporozoite titers of the magnitude observed in the murabutidetreated group can be correlated with immunity against parasite challenge (7).
DISCUSSION
Siddiqui et al. (13) have reported successful immunization of owl monkeys with liposomes containing a natural malarial merozoite antigen and a fatty acid derivative of muramyl dipeptide. In the present paper we demonstrate that a synthetic 26-amino-acid sequence representing a portion of the circumsporozoite protein of P. knowlesi (5) , when given in saline with a muramyl dipeptide derivative, murabutide, can elicit high titers of anti-peptide antibodies that recognize the native protein. Murabutide has also been shown to be adjuvant active with a TT vaccine in monkeys (A. Morin, personal communication).
The use of either Freund complete adjuvant or murabutide in primary immunization with the pep-TI resulted in potent anti-peptide responses after boosting with the conjugate in the absence of adjuvant. Although both adjuvant treatments resulted in equivalent titers of antibody capable of binding to the peptide, an important difference was observed in the ability of these antibodies to elicit the circumsporozoite reaction. This in vitro test has been shown to have a positive correlation with the degree of protection in mice and monkeys (4) . The use of alum as the adjuvant resulted in high anti-peptide antibody titers only after a third immunization with pep-TT. Even then these antibodies recognized the native protein less well than the murabutide group as judged by RIA, immunofluorescence, and the circumsporozoite reaction.
An attempt was made to decrease the need for repeated injections of TT and thus the total amount of carrier given in the primary and secondary immunization, since TT itself is a potent immunogen. Immunization with two doses of the peptide itself in adjuvant, in the absence of carrier protein, was unsuccessful, possibly due to the small size of the peptide. To increase the length of the peptide in the hopes that it could then act as both hapten and carrier, the peptide was polymerized. Utilization of the polymerized peptide after priming with pep-TT resulted in an elevated anti-peptide response. Similar attempts to reduce the amount of carrier protein used have been successful in the streptococcal M protein model system (9) .
It is also possible to copolymerize the adjuvant with the peptide to make a longer synthetic immunogen that has inherent adjuvanticity. In this way, the need for the larger carrier molecule can often be eliminated (9) . Experiments are underway to test the efficacy of immunization with a muramyl dipeptide-lysine-malaria peptide copolymer, thus avoiding the use of TT even in the primary immunization.
Preliminary experiments in rhesus monkeys suggest an important role for the carrier molecule in eliciting a good anti-peptide response. Two monkeys immunized with pep-TT and murabutide produced good anti-peptide RIA titers (5,000 to 10,000), whereas two monkeys immunized with peptide conjugated to bovine gamma globulin and murabutide produced only low anti-peptide titers (10 to 80) as measured by RIA. Thus, TT appears to be a suitable carrier, whereas bovine gamma globulin is not (J. Barnwell, unpublished results). However, administered in saline, even when conjugated to TI, the peptide did not elicit biologically active antibodies unless the conjugate had been associated with murabutide. Other factors that may be important in eliciting the anti-peptide response while stimulating a minimal anti-carrier response are being explored, including the degree of substitution of peptide and adjuvant on the carrier. LITERATURE CITED
